ANGELALIGN TECHNOLOGY INC.

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6699)

POSITIVE PROFIT ALERT

This announcement is made by Angelalign Technology Inc. (時代天使科技有限公司) (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Listing Rules.

The board of directors of the Company (the "**Board**") is pleased to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment of the Group's unaudited management accounts for the six months ended June 30, 2026 ("**2026 H1**", the "**Reporting Period**") and the latest information available, during 2026 H1, the Group is expected to record:

1. A total clear aligner case volume of approximately 316,600, representing an increase of 40.2% compared to approximately 225,800 for the six months ended June 30, 2025 ("**2025 H1**"). Among which, case volume in global markets (ex-Chinese mainland) increased by 43.3% to approximately 168,000, and in the Chinese mainland market increased by 36.8% to approximately 148,600;

2. A total revenue in the range of approximately USD229.0 million to USD231.0 million, representing an increase of 41.9% to 43.1% compared to USD161.4 million for 2025 H1; and

3. A net profit in the range of approximately USD24.0 million to USD25.4 million, representing an increase of 69.0% to 78.9% compared to USD14.2 million for 2025 H1.

The Board considers that the expected improvements in the Group's performance are primarily attributable to:

1. Doctors in diverse segments moved towards clinically proven aligners, which benefited the Group

After trying different brands, dental professionals and patients realized that even though aligners all look similar, the treatment results are significantly different. As a result, market demand for clinically proven aligners and services continued to increase. Dental professionals increasingly chose our products and services which are heavily clinically focused.

Benefiting from this trend, during the Reporting Period, the Group's case volume continued to grow rapidly across global markets. Professional brand and clinician recognition continued to strengthen. Net Promoter Scores (NPS) remained at a high level.

In the global adolescent/paediatric patient market, a consistent and scientifically rigorous system is even more crucial. During the Reporting Period, the Group gained recognition from this group of clinicians and patients, which in turn drove rapid growth in the Group's adolescent/paediatric segment.

Meanwhile, even in the lower-tier markets of China, clinicians cared about their professional reputation and patient experience, which drove them to proven professional products and services such as those offered by the Group. This in turn drove rapid growth of the Group's business in the Chinese mainland market during the Reporting Period.

2. **Heavy investments in professional branding, direct sales and local customer service infrastructure in the past several years have begun to deliver operating leverage and improved profitability**

The Group spent several years building its global direct sales network, localized customer service system, and clinical support infrastructure. These systems are now operating smoothly while continuing to improve.

As the Group's business continued to grow, professional brand leadership, economies of scale and operating leverage increased. Prior strategic investments are seeing improved operating efficiency and profitability, laying a solid foundation for long-term sustainable growth.

Looking ahead, the Group remains committed to serving dental professionals directly, and continues to strengthen localized clinical support, customer service, and professional training systems, while phasing out OEM and channel businesses with low customer stickiness and limited pricing stability.

3. **Open management culture of the Group helped to integrate diverse professional talents and clinical insights, and accelerated product and service innovation**

China, Europe, North America, South America, and Asia Pacific each has unique clinical practices and professional capabilities. Orthodontic professionals worldwide have high intellectual capacity and desire for learning, sharing and research collaboration. The Group's open culture and diverse team enabled it to collaborate closely with multinational talents, which accelerated the Group's innovation in clinical products, clinical software, and support services. This attracted more customers to work with us globally and in China during the Reporting Period.

As of the date of this announcement, the Company is finalizing the Group's 2026 H1 interim results, and the information herein is based on a preliminary assessment by the management of the Company with reference to currently available information, including the Group's management accounts which have not been audited or reviewed by the Company's auditors or the audit committee of the Company. Actual results may differ and are subject to further adjustments. Shareholders and potential investors are advised to read the Group's 2026 H1 interim results announcement, which is expected to be published before the end of August 2026 pursuant to the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Angelalign Technology Inc.
Mr. FENG Dai
Chairman

Hong Kong, July 31, 2026

As at the date of this announcement, the Board comprises Mr. FENG Dai, Mr. HU Jiezhang, Mr. HUANG Kun and Ms. DONG Li as executive Directors; Mr. HAN Xiaojing, Mr. SHI Zi and Mr. ZHOU Hao as independent non-executive Directors.